Comments
Bengaluru-based Biocon Ltd reported a net profit of ₹753.3 crore in the third quarter of FY24, against a loss of ₹20.7 crore recorded in the same quarter last year.
The revenue from operations increased 34.4 per cent to ₹3,953.7 crore (₹2,941 crore).
On a sequential basis, revenue from operations increased 14 per cent from ₹3,462.3 crore. While net profit increased significantly from ₹172.7 crore in Q2.
Kiran Mazumdar Shaw, Executive Chairperson, Biocon, and Biocon Biologics, said, “Consolidated EBITDA at ₹1,492 crore grew 106 per cent. A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of $200 million towards the acquisition-related debt reduction. We continue to make steady progress towards strengthening the foundation for a sustainable growth across all three business segments.”
Expenses increase
The company’s expenses increased 36 per cent to ₹3,708 crore (₹2,718 crore). On a sequential basis, expenses increased 10 per cent from ₹3,357.7 crore.
Nehal Vora, Global Head of Commercial APIs, and Indranil Sen, Chief Financial Officer, have resigned from Biocon Ltd, the company said in an exchange filing.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.